Analyst picks & changes

Amgen Inc.


Immunex Corp.


Analysts were virtually unanimous in concluding that a positive FDA advisory panel review of IMNX's request for a label expansion for


GM-CSF will have little or no impact on sales of the colony stimulating factor, and hence no impact on the market dominance of AMGN's


G-CSF (see page B4). The company has requested labels for both chemotherapy-induced neutropenia (CIN) and

Read the full 707 word article

How to gain access

Continue reading with a
two-week free trial.